Evaluation of acyclovir treatment results in the treatment and improvement of anal fissure in non-HSV patients

Abstract

Acute anal fissure is a linear ulcer in the anal region of the distal canal to the indentation line of the anal canal. A very common disease, which affects both sexes, especially young people. Its clinical symptoms include pain during and after defecation and bleeding. Due to the fact that Fisher's anal disease statistically affects a high level of society and is a common disease, so in this study we intend to investigate the usefulness of acyclovir in the treatment of acute anal fissure in non-herpes patients. Methods: In this clinical trial study, 120 patients who had referred to the surgical clinic of Imam Reza Hospital in Tabriz between October 2020 and March 2022 were diagnosed with acute anal fissure. Using a checklist containing patient information including age, sex, pain rate, bleeding rate, pruritus and constipation, diarrhea and pruritus Patient information was recorded and evaluated. Results: In this study, 120 patients were included in the study. Of these, 75 (62.5%) were male and 45 (37.5%) were female. In the diagnosis of patients at referral, the most common causes of referrals include pain during defecation in 120 patients (100%), bleeding in 89 patients (74.2%), constipation in 63 patients (52.5%), pruritus in 49 patients ( 40.8%) and diarrhea in 17 patients (14.2%). There was no significant difference between the mean pain of patients in the two groups in the second and fourth weeks after treatment according to VAS criteria. Complete recovery was achieved in 37 patients after the second week, 17 of whom were in the diltiazem group and 20 in the acyclovir group (P value = 0.553). In terms of patient satisfaction, in general, the satisfaction of patients in the acyclovir group was higher than the diltiazem group, but the difference was not significant.